查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1584744

抗高血壓藥物市場：按藥物類別、劑型、適應症、分銷管道、最終用戶分類 - 全球預測 2025-2030

Antihypertensive Drugs Market by Drug Class, Form, Indication, Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗高血壓藥物市場規模預估為247億美元，預估2024年將達257.6億美元，複合年成長率為4.66%，2030年將達339.9億美元。

抗高血壓藥物市場的特點是市場廣闊，涵蓋旨在控制高血壓和相關心血管疾病的多類藥物，包括利尿劑、ACE抑制劑、鈣通道阻斷劑和ARB。高血壓通常被稱為“沉默的殺手”，其盛行率和潛在的嚴重健康後果使得這些藥物的應用成為必要，這使得它們成為世界各地醫療保健策略的一個組成部分。最終用途主要包括醫院、診所、居家醫療，顯示其適用於各種病患群體。影響成長的主要因素包括由於人口變化、生活方式的改變以及心血管健康意識的增強而導致高血壓盛行率的增加。世界人口老化是一個主要因素，因為老年人更容易患高血壓。藥物配方和藥物傳遞的技術進步也刺激了市場的擴張。個人化醫療存在新的機遇，藥物基因組學可能會帶來針對個人遺傳特徵的更有效的抗高血壓治療方案。此外，擴大新興市場的醫療保健服務也代表著市場開拓的重大機會。然而，與抗高血壓藥物相關的副作用以及圍繞藥物核准的嚴格監管環境等限制可能會阻礙市場成長。其他挑戰包括專利藥物對非專利的侵蝕以及替代療法的競爭，包括生活方式干涉和整體方法。需要技術創新的領域包括開發提高療效同時最大限度減少副作用的聯合治療，以及使用奈米顆粒等新型藥物傳輸系統。此外，闡明抗藥性機制的研究可能會帶來改善藥物反應性的治療方法。抗高血壓藥物市場是一個由臨床需求、技術創新和經濟因素驅動的動態市場，未來的成長預計將透過克服監管挑戰、解決患者依從性問題以及開發提高藥物療效和可及性的技術來推動。撬動進步。

主要市場統計
基準年[2023] 247億美元
預測年份 [2024] 257.6億美元
預測年份 [2030] 339.9億美元
複合年成長率（%） 4.66%

市場動態：揭示快速發展的抗高血壓市場的關鍵市場洞察

供需的動態交互作用正在改變抗高血壓藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 老年人口增加導致高血壓盛行率快速上升
    • 全球醫療保健支出增加
    • 提高消費者早期診斷與治療意識
  • 市場限制因素
    • 核准流程嚴格，藥品研發成本大
  • 市場機會
    • 介紹一類新型抗高血壓藥物
    • 新藥認證快速增加
  • 市場挑戰
    • 對抗高血壓藥物造成健康損害的擔憂

波特五力：駕馭抗高血壓藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗高血壓藥物市場的外部影響

外部宏觀環境因素在塑造抗高血壓藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解抗高血壓藥物市場的競爭狀況

抗高血壓藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣抗高血壓藥物市場供應商績效評估

FPNV定位矩陣是評估抗高血壓藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了抗高血壓藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，抗高血壓藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 高血壓盛行率迅速上升，老年人口增加
      • 世界各地的醫療費用增加
      • 提高消費者早期診斷與治療意識
    • 抑制因素
      • 藥物研發需要嚴格的核准流程和龐大的成本。
    • 機會
      • 介紹一類新型抗高血壓藥物
      • 新藥認證快速增加
    • 任務
      • 對抗高血壓藥物對健康的負面影響的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的抗高血壓藥物市場

  • α阻斷劑
  • 血管張力素轉化酵素抑制劑
  • 血管收縮素受體阻斷劑
  • BETA受體阻斷劑
  • 鈣離子通道阻斷劑
  • 利尿劑
  • 腎素抑制劑
  • 血管擴張劑

第7章 抗高血壓藥物市場：依形式

  • 靜脈注射
  • 口服錠劑/膠囊
  • 經皮吸收貼片

第8章 依適應症分類的降血壓藥市場

  • 原發性高血壓
  • 次發性高血壓

第9章 抗高血壓藥物市場：按分銷管道

  • 離線
  • 線上

第 10 章 抗高血壓藥物市場：依最終使用者分類

  • 居家護理設施
  • 醫院/診所

第11章 北美和南美抗高血壓藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區降血壓藥市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的抗高血壓藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Alembic Pharmaceuticals Limited
  • Alkem Laboratories
  • Apikos Pharma
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Centurion Remedies Private Limited
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi SA
  • Saphnix Lifesciences
  • Schwitz Biotech
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • United Therapeutics Corporation
  • Zydus Lifesciences Limited
Product Code: MRR-B16853778279

The Antihypertensive Drugs Market was valued at USD 24.70 billion in 2023, expected to reach USD 25.76 billion in 2024, and is projected to grow at a CAGR of 4.66%, to USD 33.99 billion by 2030.

The market for antihypertensive drugs is characterized by a broad scope encompassing multiple classes of medications, including diuretics, ACE inhibitors, calcium channel blockers, and ARBs, aimed at managing hypertension and associated cardiovascular conditions. Hypertension, often dubbed the "silent killer," necessitates the application of these drugs due to its prevalence and potential for severe health implications, making it integral to healthcare strategies worldwide. The end-use scope primarily spans hospitals, clinics, and home healthcare settings, underscoring its extensive application among varying patient demographics. Key factors influencing growth include increasing incidences of hypertension due to demographic shifts, lifestyle changes, and heightened awareness of cardiovascular health. The aging global population is a significant driver, as older adults are more prone to high blood pressure. Technological advancements in drug formulations and delivery mechanisms also spur market expansion. Emerging opportunities exist in personalized medicine, where pharmacogenomics could guide more effective antihypertensive regimens tailored to individual genetic profiles. Furthermore, expanding healthcare access in developing regions presents a substantial opportunity for market penetration. However, limitations such as the side effects associated with antihypertensive medications and the strict regulatory landscape governing drug approval can hinder market growth. Challenges also arise from the generic erosion of patented medicines and competition from alternative therapies, including lifestyle interventions and holistic approaches. Areas ripe for innovation include the development of combination therapies that enhance efficacy while minimizing side effects and the exploitation of novel drug delivery systems such as nanoparticles. Additionally, research into understanding resistance mechanisms could lead to breakthroughs that improve drug responsiveness. The antihypertensive drug market is dynamic, driven by clinical demand, innovation, and economic factors, with future growth dependent on navigating regulatory landscapes, addressing patient compliance issues, and capitalizing on technological advances to improve drug efficacy and accessibility.

KEY MARKET STATISTICS
Base Year [2023] USD 24.70 billion
Estimated Year [2024] USD 25.76 billion
Forecast Year [2030] USD 33.99 billion
CAGR (%) 4.66%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antihypertensive Drugs Market

The Antihypertensive Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surging prevalence of hypertension, along with the growing geriatric population
    • Increase in healthcare expenditure worldwide
    • Growing consumer awareness of early diagnosis and treatment
  • Market Restraints
    • Stringent approval process and huge costs involved in drug development
  • Market Opportunities
    • Introduction of a new class of antihypertensive drugs
    • Surge in approvals of novel drugs from regulatory bodies
  • Market Challenges
    • Concern regarding adverse health outcomes of antihypertensive drugs

Porter's Five Forces: A Strategic Tool for Navigating the Antihypertensive Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antihypertensive Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antihypertensive Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antihypertensive Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antihypertensive Drugs Market

A detailed market share analysis in the Antihypertensive Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antihypertensive Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antihypertensive Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antihypertensive Drugs Market

A strategic analysis of the Antihypertensive Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antihypertensive Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alembic Pharmaceuticals Limited, Alkem Laboratories, Apikos Pharma, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Centurion Remedies Private Limited, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Glenmark Pharmaceuticals Ltd., Johnson & Johnson Services, Inc., Lupin Ltd., Merck & Co., Inc., Novartis AG, Sanofi S.A., Saphnix Lifesciences, Schwitz Biotech, Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Antihypertensive Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Alpha-Blockers, Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Beta-Blockers, Calcium Channel Blockers, Diuretics, Renin Inhibitors, and Vasodilators.
  • Based on Form, market is studied across Intravenous Injections, Oral Tablets/Capsules, and Transdermal Patches.
  • Based on Indication, market is studied across Primary Hypertension and Secondary Hypertension.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on End-User, market is studied across Home Care Facilities and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surging prevalence of hypertension, along with the growing geriatric population
      • 5.1.1.2. Increase in healthcare expenditure worldwide
      • 5.1.1.3. Growing consumer awareness of early diagnosis and treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent approval process and huge costs involved in drug development
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of a new class of antihypertensive drugs
      • 5.1.3.2. Surge in approvals of novel drugs from regulatory bodies
    • 5.1.4. Challenges
      • 5.1.4.1. Concern regarding adverse health outcomes of antihypertensive drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antihypertensive Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Alpha-Blockers
  • 6.3. Angiotensin Converting Enzyme Inhibitors
  • 6.4. Angiotensin Receptor Blockers
  • 6.5. Beta-Blockers
  • 6.6. Calcium Channel Blockers
  • 6.7. Diuretics
  • 6.8. Renin Inhibitors
  • 6.9. Vasodilators

7. Antihypertensive Drugs Market, by Form

  • 7.1. Introduction
  • 7.2. Intravenous Injections
  • 7.3. Oral Tablets/Capsules
  • 7.4. Transdermal Patches

8. Antihypertensive Drugs Market, by Indication

  • 8.1. Introduction
  • 8.2. Primary Hypertension
  • 8.3. Secondary Hypertension

9. Antihypertensive Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Offline
  • 9.3. Online

10. Antihypertensive Drugs Market, by End-User

  • 10.1. Introduction
  • 10.2. Home Care Facilities
  • 10.3. Hospitals & Clinics

11. Americas Antihypertensive Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antihypertensive Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antihypertensive Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alembic Pharmaceuticals Limited
  • 3. Alkem Laboratories
  • 4. Apikos Pharma
  • 5. AstraZeneca PLC
  • 6. Bayer AG
  • 7. Boehringer Ingelheim International GmbH
  • 8. Centurion Remedies Private Limited
  • 9. Daiichi Sankyo Co., Ltd.
  • 10. Dr. Reddy's Laboratories
  • 11. F. Hoffmann-La Roche AG
  • 12. Gilead Sciences, Inc.
  • 13. Glenmark Pharmaceuticals Ltd.
  • 14. Johnson & Johnson Services, Inc.
  • 15. Lupin Ltd.
  • 16. Merck & Co., Inc.
  • 17. Novartis AG
  • 18. Sanofi S.A.
  • 19. Saphnix Lifesciences
  • 20. Schwitz Biotech
  • 21. Sun Pharmaceutical Industries Limited
  • 22. Takeda Pharmaceutical Company Limited
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. United Therapeutics Corporation
  • 25. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. ANTIHYPERTENSIVE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANTIHYPERTENSIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANTIHYPERTENSIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIHYPERTENSIVE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIHYPERTENSIVE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ALPHA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN CONVERTING ENZYME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INTRAVENOUS INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL TABLETS/CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PRIMARY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY SECONDARY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. ANTIHYPERTENSIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. ANTIHYPERTENSIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023